- Dr. Annabelle will lead the science advisory team to fill knowledge gaps that are prominent throughout the global cannabis industry
- Focus will be to examine the therapeutic application of cannabinoids on specific disease conditions
- Advisory team will accelerate the production of cannabis products with claims backed by scientific data
- As part of these R&D efforts, clinical trials will be activated as soon as the necessary protocols are completed
TORONTO, June 17, 2021 (GLOBE NEWSWIRE) — Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has appointed Dr. Annabelle Manalo-Morgan, PhD, as Lead Scientific Advisor to further the research and development of unique product formulations and to educate individuals on the benefits of cannabinoid and plant-based medicine.
Dr. Annabelle is a scientist, educator, author, mother of five, and a respected key opinion leader. She is a cell and developmental biologist from Vanderbilt University in Nashville, Tennessee, with a background in neuroscience from Georgetown University. She earned her PhD in Cell and Developmental Biology with a focus in Cardio-Oncology and has since become a philanthropist and entrepreneur focused on pharmaceutical innovation and clinical trial research in medical cannabis.
“We are very pleased to welcome Dr. Annabelle to the Flora Growth team where she will be instrumental in the future of Flora’s product development, research and educational efforts,” said Luis Merchan, President and CEO of Flora. “Flora has always been very passionate about its medical divisions and views them as foundational components of the Company as it expands its global presence. The formation of this advisory team led by Dr. Annabelle will streamline our research and development efforts and help speed up growth initiatives as we work together to launch targeted cannabis products and increase distribution across all channels.”
During her training, Dr. Annabelle experienced life-changing personal trauma that shifted her focus toward alternative medicine and natural health consciousness. Over the past 6 years, she has dedicated herself to educating individuals worldwide on the complexity of disease and the significance of utilizing natural components of plants, such as cannabis, to make medicine a more efficient, safe and personalized process. She consults on medical cannabis legalization, standards and protocols for a variety of countries and firms, and is currently conducting advanced research and product development focused on the therapeutic application of specific cannabinoids in disease conditions.
“The need for research and innovative product development has never been greater as the cannabis industry continues its exponential growth and acceptance around the world. Current solutions often leave consumers, patients and healthcare professionals with few options aside from a low-and-slow approach while trialing numerous products and product formats,” added Dr. Annabelle. “I’m extremely excited to be working with the Flora team as we are aligned on creating and bringing to market novel products that have a superior safety profile and are more efficacious than existing cannabis treatment options.”
Flora Announces CEO Fireside Highlighting Recent Developments
Further Flora Growth will be hosting another live fireside discussion between President & CEO, Luis Merchan, and Vice President of Corporate Development, James Williams. The virtual fireside conversation will take place on Thursday, June 24th at 1:00 pm ET and all those interested in attending are encouraged to register using the following link.
Registration Link:
https://us02web.zoom.us/webinar/register/WN_9dTiVRXpQ0qfKOIBXJBSdQ
Specifically, Luis and James will provide an overview of the recent Hoshi and Heimat announcements, including their strategic importance to our international expansion and expected contributions to our revenue growth. They will also discuss the latest management additions and outline Flora Growth’s approach to securing exceptional human capital to execute on its growth plans.
About Flora Growth Corp.
Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.floragrowth.ca or follow @floragrowthcorp on social for more information.
Investor Relations Contact:
Evan Veryard
+1 416 571 9037
evan.veryard@floragrowth.ca
Public Relations Contact:
Cassandra Dowell
+1 (858) 264-6600
flora@cmwmedia.com
Cautionary Statement Concerning Forward-Looking Statements
This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: the impact of additions to our advisory team; our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this document and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.
